Hikma Pharmaceuticals (LON:HIK) Stock Rating Reaffirmed as “Buy” by Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by analysts at Jefferies Financial Group in a research report issued to clients and investors on Friday, Digital Look reports. They currently have a GBX 2,025 target price on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 25.93% from the company’s current price.

A number of other research analysts also recently commented on the company. Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Citigroup upped their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

LON:HIK opened at GBX 1,608 on Friday. The company has a market cap of £3.33 billion, a price-to-earnings ratio of 9.14, a PEG ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 1,865. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The stock has a fifty day moving average price of GBX 1,602.32 and a 200-day moving average price of GBX 1,475.50.

Insider Activity

In related news, insider Tobias Hestler acquired 7,500 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.26% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.